Guardant Health Inc (NASDAQ:GH) insider Richard B. Lanman sold 63,075 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $105.25, for a total value of $6,638,643.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Guardant Health stock opened at $98.93 on Friday. The firm has a market capitalization of $9.18 billion and a price-to-earnings ratio of -35.33. Guardant Health Inc has a fifty-two week low of $27.04 and a fifty-two week high of $112.21. The stock’s fifty day moving average is $92.39 and its two-hundred day moving average is $76.41.
Guardant Health (NASDAQ:GH) last posted its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.21. The company had revenue of $53.98 million for the quarter, compared to analyst estimates of $35.97 million. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. Guardant Health’s revenue was up 178.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.75) earnings per share. On average, equities research analysts anticipate that Guardant Health Inc will post -1.27 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $125.00 price objective (up previously from $96.00) on shares of Guardant Health in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price objective on Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Zacks Investment Research lowered Guardant Health from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 10th. Finally, Cowen set a $110.00 price objective on Guardant Health and gave the stock a “buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $111.80.
A number of institutional investors have recently bought and sold shares of the business. NEXT Financial Group Inc grew its holdings in Guardant Health by 20.0% in the second quarter. NEXT Financial Group Inc now owns 1,200 shares of the company’s stock valued at $104,000 after purchasing an additional 200 shares during the last quarter. First Trust Advisors LP grew its holdings in Guardant Health by 0.4% in the first quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock valued at $5,513,000 after purchasing an additional 264 shares during the last quarter. Advantage Investment Management LLC grew its holdings in Guardant Health by 200.0% in the second quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock valued at $39,000 after purchasing an additional 300 shares during the last quarter. Rhumbline Advisers grew its holdings in Guardant Health by 1.8% in the first quarter. Rhumbline Advisers now owns 20,247 shares of the company’s stock valued at $1,553,000 after purchasing an additional 367 shares during the last quarter. Finally, Pendal Group Ltd grew its holdings in Guardant Health by 8.8% in the second quarter. Pendal Group Ltd now owns 4,845 shares of the company’s stock valued at $418,000 after purchasing an additional 390 shares during the last quarter. 72.78% of the stock is currently owned by institutional investors.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Recommended Story: Channel Trading
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.